Haleon Pakistan Limited (PSX: HALEON) has announced the commencement of commercial manufacturing for Panadol 500mg tablets at its dedicated facility in Jamshoro, Pakistan.
The development was officially communicated to the Pakistan Stock Exchange (PSX). This in-house production follows a strategic investment disclosed on October 13, 2023, aimed at integrating advanced manufacturing technologies and expanding local production capabilities.
As part of this transition, Panadol 500mg tablets produced at Jamshoro will feature a updated tablet design, incorporating a beacon engraving instead of the standard 'Panadol' text. The company confirmed that product quality and therapeutic efficacy remain unchanged, marking a positive operational milestone for local product availability.
Read the full story on the original publisher’s website.
Open original article